Tag Archives: osteoarthritis drug program

Summary & Results from Osteoarthritis Patient-Focused Drug Development Meeting

Our patients have spoken: “We want earlier diagnoses to stop disease progression and better biomarkers for earlier diagnosis”

On March 8th, 2017, the Arthritis Foundation, US Food and Drug Administration (FDA), osteoarthritis (OA) patients, drug developers, health care providers and academic researchers came together to discuss the serious burden of OA disease, particularly the most significant OA-related symptoms, the impact of those symptoms, currently available treatments and ideal treatments.

Continue reading Summary & Results from Osteoarthritis Patient-Focused Drug Development Meeting